Semler Scientific, Inc. (SMLR)
NASDAQ: SMLR · Real-Time Price · USD
29.97
-0.71 (-2.31%)
At close: Nov 4, 2024, 4:00 PM
31.00
+1.03 (3.44%)
Pre-market: Nov 5, 2024, 8:08 AM EST

Company Description

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States.

The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.

It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing.

The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers.

It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Semler Scientific, Inc.
Semler Scientific logo
Country United States
Founded 2007
IPO Date Feb 21, 2014
Industry Medical Devices
Sector Healthcare
Employees 92
CEO Douglas Murphy-Chutorian

Contact Details

Address:
2340-2348 Walsh Avenue, Suite 2344
Santa Clara, California 95051
United States
Phone 877 774 4211
Website semlerscientific.com

Stock Details

Ticker Symbol SMLR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001554859
CUSIP Number 81684M104
ISIN Number US81684M1045
Employer ID 26-1367393
SIC Code 3845

Key Executives

Name Position
Dr. Douglas Murphy-Chutorian M.D. Chief Executive Officer, President and Director
Renae Cormier Chief Financial Officer, Principal Accounting Officer, Head of Corporate Communications and Business Strategy and Secretary
Dr. Herbert J. Semler Founder and Chairman Emeritus
Jennifer Oliva Herrington Chief Operating Officer
Shane Reid Chief Technology Officer
Cindy Guinasso Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Nov 4, 2024 8-K Current Report
Oct 21, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 8, 2024 8-K Current Report
Sep 6, 2024 144/A Filing
Sep 6, 2024 144/A Filing
Aug 29, 2024 144 Filing
Aug 29, 2024 144 Filing
Aug 26, 2024 8-K Current Report
Aug 23, 2024 ARS Filing
Aug 23, 2024 DEF 14A Other definitive proxy statements